Christina Migliore, MD
Pulmonary Disease · Newark, NJNPI 1508883752
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,510 of the $26,560 with a category attached, or 69.7%. Actelion Pharmaceuticals US, Inc. accounts for 76.9% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2019 at $5,210 and has fallen 64.8% since, to $1,834 in 2025. Among pulmonary disease clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 502 payments — averaging $52.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$20K
- GSK$1K
- United Therapeutics Corporation$826
- Boehringer Ingelheim$601
- Astellas Pharma US Inc$506
- AstraZeneca$324
- plus $3K from 31 others
Across 47 payments — averaging $1362.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Actelion Pharmaceuticals, Ltd$27K
- United Therapeutics Corporation$20K
- Janssen Research & Development, LLC$9K
- Bayer$8K
What the payments were for
- Speaking & faculty fees$18,51070%
- Food & beverage$7,60229%
- Education$4482%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 117 | $20,422 |
| GSK | 86 | $1,213 |
| United Therapeutics Corporation | 60 | $826 |
| Boehringer Ingelheim | 40 | $601 |
| Astellas Pharma US Inc | 16 | $506 |
| AstraZeneca(2 entities) | 20 | $324 |
| Sanofi | 16 | $306 |
| Merck | 17 | $276 |
| Mylan Specialty L.p. | 16 | $271 |
| Insmed, Inc. | 19 | $265 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $233 |
| Bayer | 16 | $231 |
| AbbVie | 11 | $122 |
| Viatris Specialty LLC | 6 | $118 |
| Eurofins Viracor, LLC | 1 | $87 |
| Mallinckrodt Hospital Products Inc. | 5 | $82 |
| CMP Pharma, Inc. | 4 | $67 |
| ANI Pharmaceuticals, Inc. | 4 | $58 |
| Johnson & Johnson | 3 | $54 |
| Vifor Pharma, Inc. | 3 | $51 |
| Boston Scientific | 3 | $49 |
| Genentech USA, Inc. | 3 | $41 |
| Gilead | 3 | $41 |
| Novo Nordisk | 2 | $33 |
| Kamada Ltd. | 1 | $33 |
| Regeneron Healthcare Solutions, Inc. | 2 | $31 |
| 3b Medical, Inc. | 1 | $31 |
| Shire North American Group Inc | 2 | $28 |
| Akcea Therapeutics, Inc. | 2 | $26 |
| La Jolla Pharmaceutical Company | 1 | $24 |
| Atricure, Inc. | 1 | $18 |
| Electromed, Inc. | 1 | $18 |
| Invivyd Inc | 1 | $18 |
| Pfizer | 1 | $15 |
| Mallinckrodt Enterprises LLC | 1 | $15 |
| Harmony Biosciences LLC | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,560 in reported general payments places this provider in the 90th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 247 | $3,104,703 |
| UptraviSelexipag | 103 | $2,331,633 |
| Tyvaso DpiTreprostinil | 51 | $1,183,008 |
| RemodulinTreprostinil Sodium | 54 | $517,404 |
| Orenitram ErTreprostinil Diolamine | 22 | $348,599 |
| AdempasRiociguat | 25 | $337,420 |
| LetairisAmbrisentan | 15 | $198,804 |
| AdcircaTadalafil | 41 | $194,394 |
| TracleerBosentan | 12 | $139,790 |
| Ambrisentan | 29 | $68,140 |
| Tadalafil | 111 | $60,627 |
| Pirfenidone | 22 | $42,851 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $18,112 |
| Bosentan | 11 | $18,040 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $2,210 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi, Tracleer, Bosentan | $20,422 | $5,594,165373 claims |
| United Therapeutics CorporationRemodulin, Adcirca | $826 | $711,79895 claims |
| BayerAdempas | $231 | $337,42025 claims |
| GileadLetairis | $41 | $198,80415 claims |
| GSKTrelegy Ellipta | $1,213 | $18,11223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in Newark
- Richard MillerNewark$328K
- Yazan AbdeenNewark$44K
- Pratik PatelNewark$16K
- Joseph HoffmanPark Ridge$1.1M
- Reynold PanettieriNew Brunswick$1M
- Robert SussmanSummit$551K
- Manuel CunananMillville$489K
- Emanuele SantomauroHackensack$420K
- Jason ShatkinParamus$282K
- Anthony RickettiTrenton$225K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.